ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

XEN Xenetic Bio

6.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Xenetic Bio LSE:XEN London Ordinary Share GB00B08NWV55 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Xenetic Bio Share Discussion Threads

Showing 4326 to 4346 of 4450 messages
Chat Pages: 178  177  176  175  174  173  172  171  170  169  168  167  Older
DateSubjectAuthorDiscuss
12/8/2015
18:33
Buywell3- stop posting this old information. Ramping is not going to do it. Real news will.!!!!!!
smcl
11/8/2015
15:21
Why Global Healthcare Companies Have Invested in Xenetic Biosciences


Posted on August 6th, 2015




My name is Scott Maguire, CEO of Xenetic Biosciences, Inc. (OTCQB: XBIO), and I am pleased to welcome you to my inaugural blog. As we are fairly new to the US, I would like to use this opportunity to introduce you to Xenetic and our promising novel drug developments that we are driving through clinical trials with some of the world’s leading players in healthcare.

Xenetic was founded in 1997 as a spin off from University College London School of Pharmacy by Professor Gregory Gregoriadis, one of the leading researchers in drug delivery. As a result of his and our research and development team, the Company holds over 147 US and international patents issued and more than 90 patents pending. This is by any measure a vast patent estate, especially for a small cap biotech company. It is our expectation that, as Xenetic grows its capital base, we will be able to use these patents to create more novel therapies and ultimately contribute to improving global health.

In January of 2014, Xenetic relocated its research base from London to Lexington, Massachusetts, just north of Boston, tapping into the wealth of talent in orphan drug development and market launch expertise in the greater Boston area. At the same time, the Company completed a public listing in the US on the OTCQB with the hope of raising the magnitude of capital required to drive our drug candidates through clinical development providing the potential for an eventual market launch.

Although Xenetic Biosciences is only a small company at present, I believe that the future and outlook is bright given the scale and importance of our current license deals as well as our strategic shareholders and proprietary drug candidates. We are fortunate to have several cornerstone and deep-pocketed investors who have invested the majority of the invested capital to date. These cornerstone shareholders include Rusnano via SynBio (XBIO was one of their first biotech investments), the Serum Institute of India, India’s largest biotech company and one of the world’s largest vaccine manufacturers, and Baxter International (NYSE:BAX), one of the world’s largest biopharma companies. This stable shareholder base is fully supportive of the Company’s stated ambition to up-list its shares onto a globally recognized, more liquid securities exchange such as NASDAQ, which better represents the Company’s potential and value.

Baxter is the most recognized name associated with Xenetic. Our license deal with Baxter involves developing drug candidates with an extended half-life of certain proteins and molecules using the Company’s patent-protected PolyXen® technology(utilizing chains of polysialic acid “PSA”), designed to create a longer-acting hemophilia drug than what is currently on the market. PolyXen® works by attaching a PSA chain to the drug with the objective of making the drug stay in blood circulation much longer and protecting the drug from the body’s immune system. The design of the PolyXen® technology is intended to make the drug more effective, last longer and decrease the frequency and amount of the drug. Baxter expects to commence human clinical trials on this novel hemophilia drug candidate during the first half of 2016.

Baxter is a major license partner of Xenetic, having expanded an existing license agreement with us last year. The agreement now equals $100M in potential cash payments to Xenetic in addition to royalty payments. Baxter is also a significant shareholder in Xenetic, most recently investing $10M at a price of approximately $0.94 per share, which represented a market cap of $140M at that time.

A second important initiative for Xenetic is our early stage, yet very promising drug candidate, OncoHist™, which has the potential to be a game-changer in cancer therapy. This is a drug candidate based on histone proteins that are known to naturally act against cancer cells. The base material is harvested from human cells, and when developed into OncoHist™ has shown initial promise in small clinical trials (40 subjects) in both Germany and Russia for the treatment of Acute Myeloid Leukemia (AML) and Non-Hodgkin’s Lymphoma (NHL). Our hope is that further clinical study will demonstrate that OncoHist™ provides benefit without the toxic effects of the current standards of care which destroy healthy cells as well as cancer cells.

Based on the initial European clinical data, the Dana Farber Cancer Institute, one of the world’s leading cancer medical centers, signed on as an active partner in our US clinical pursuits and is currently conducting preclinical research in the US on OncoHist™ for other indications beyond AML. It remains our priority to commence US clinical trials with OncoHist™ under an orphan drug designation for AML, followed by clinical trials for other rare cancer indications, dependent upon Xenetic’s available capital resources.

Yet another important initiative, and our most advanced clinical candidate, is ErepoXen® (polysialylated erythropoietin (“PSA-EPO̶1;) which uses the Company’s PolyXen® technology and is being studied for the treatment of anemia in Chronic Kidney Disease (CKD) patients. ErepoXen® is in a Company-sponsored Phase II clinical study in Australia and New Zealand for CKD patients. In studies of ErepoXen® in over 100 subjects across Australia, New Zealand, India and Russia, the product has been well-tolerated and is demonstrating an extended circulation time in the bloodstream.

The Company’s commercialization strategy for ErepoXen®, which we believe could be a mainstream drug addressing a substantial global market, includes seeking an out-license arrangement for the continuing development of ErepoXen® as a potential Phase II(b) candidate. Xenetic is looking for a well-capitalized license partner who is more experienced at taking large market drug candidates through the latter stages of human clinical trials and who would be better placed to execute a global market launch.

I want to thank you all for taking the time to read Xenetic’s first CEO blog. The Xenetic team and I look forward to updating you on the Company and providing insights on the therapeutic areas where we hope to make a difference.

Sincerely,

Scott Maguire

buywell3
11/8/2015
15:18
Xenetic Biosciences, Inc. – "Why Global Healthcare Companies Have Invested in Xenetic Biosciences"


08/06/15

NEW YORK, NY / ACCESSWIRE

Xenetic Biosciences, Inc. (OTCQB: XBIO) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Scott Maguire, MBA. TheChairmansBlog.com is an exclusive on-line media publication that enables key executive officers a unique platform to share insights about their company and industry trends.





In his inaugural blog, Scott Maguire discusses Xenetic's promising novel drug developments and partnerships with leading world healthcare companies such as Baxter International (NYSE: BAX). He expands on the progress of the Company's main initiatives PolyXen(R), OncoHist(TM), and ErepoXen(R) and shares Company goals moving forward. Read the full blog post from Mr. Maguire on TheChairmansBlog.com (

About Xenetic Biosciences

Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen(R), designed to develop next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs, and OncoHist(R) for the development of novel oncology drugs focused on orphan indications.

Xenetic's lead product candidates include ErepoXen(R), a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and OncoHist(R), a novel recombinant human histone H1.3 molecule for the treatment of refractory Acute Myeloid Leukemia (AML) with potential to treat numerous other cancer indications. Xenetic is collaborating with Russian-based OJSC Pharmsynthez (who is an affiliate of a significant shareholder in Xenetic) and the Serum Institute of India to test additional drug and vaccine candidates and to de-risk the development process with clinical data generated in Russia and India before Xenetic takes these candidates into the clinic in the Western markets.

Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the company's website at www.xeneticbio.com.

Baxter Healthcare:

Xenetic is working together with Baxter International Inc. to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on the PolyXen technology to conjugate PSA to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules. Baxter is one of the Company's largest shareholders having invested in a number of rounds with the most recent investment of $10M last year. The agreement is exclusive research, development and license agreement grants Baxter a worldwide, exclusive, royalty-bearing license to Xenetic's PSA patented and proprietary technology in combination with Baxter's proprietary molecules designed for the treatment of blood and bleeding disorders. Under the agreement, Xenetic may receive regulatory and sales target receipts for total potential milestones of up to $100 million plus royalties on sales.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: TheChairmansBlog.com

buywell3
11/8/2015
15:15
Baxter bought 10 million shares in XEN at $1 a share just over a year back after Xenetic moved into the USA.

Xenetic are already figuring large in Baxters Factor VIII plans

[...]


Baxter are spitting into 2 units this year




Could it be that the delay in listing is because Baxter wants to buy Xenetic before it lists ?

buywell3
11/8/2015
14:52
Xenetic Biosciences Inc. (OTCBB:XBIO) a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics today provided an update on recent patent grants and allowances worldwide.

Since May 2014 the Company has been issued 10 patents including six in the U.S. two in Japan and one each in New Zealand and India. In addition 13 patents have been allowed including seven in the U.S. two each in Japan and South Korea and one each in Russia and Canada. Xenetic Biosciences now has over 140 issued patents worldwide and approximately 80 pending patents.

Select key patents issued recently by the U.S. Patent and Trademark Office include Patent No. 8796207 Derivatisation of erythropoietin (EPO) which relates to novel polysaccharide derivatives of EPO and methods for producing such derivatives. The derivatives are useful for improving the stability pharmacokinetics and pharmacodynamics of EPO. This same patent was also issued in Japan during the third quarter.

U.S. Patent No. 8735557 Activated sialic acid derivatives for protein derivatisation and conjugation was also recently granted and relates to polysialic acid and derivatives of polysialic acids which have terminal sialic acid units. This patent covers the targeted conjugation of polysialic acid and its derivatives to therapeutics such as peptides proteins drugs drug delivery systems etc.

Also issued during the third quarter was U.S. Patent No. 8828405 Method to Enhance an Immune Response of Nucleic Acid Vaccination. This patent relates to a composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein. The composition provides an improved immune response compared with mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein.

“Xenetic Biosciences has a substantial patent portfolio to rival any biotech company many times our size. This work results directly from our previous strategy focused on research. Now that we have transformed into a clinical development company we are well positioned for potentially monetizing our extensive intellectual property portfolio. We expect to add 13 additional patents over the next three months” said M. Scott Maguire chief executive officer of Xenetic Biosciences. “We are particularly pleased with our intellectual property position in Japan as those patent grants are typically difficult to secure. Our IP relates not only to our ‘bio-better’ EPO our lead candidate but also to improving availability of a number of protein-based drugs. We recently received an allowance for a U.S. patent relating to novel polysaccharide derivatives of granulocyte colony-stimulating factor (GCSF) and methods for producing such derivatives. The derivatives are useful for improving the stability pharmacokinetics and pharmacodynamics of GCSF. Our expectations are that we will have strong intellectual property protection for many years after our lead compounds have progressed through the U.S. regulatory process” Mr. Maguire added.

buywell3
11/8/2015
14:41
Have Xenetic got their timing right in relocating to Boston USA to set up its new HQ ?




Re above post

buywell3
11/8/2015
12:38
Next Stop Nasdaaq!

Hopefully early Q4

trotterstrading
05/8/2015
06:19
XEN raising of capital in the USA is imminent

Note USA comments here




Have XEN chosen the right place in the USA to locate to ?

buywell3
01/8/2015
08:10
SP picking up again
buywell3
30/7/2015
06:46
Significant Clinical and Corporate Milestone Newsflow

 2H15 – Submission of orphan drug application in U.S./EU for an additional
OncoHist™ indication
 1H16 – Planned U.S. IND filing for AML
 1H16 - Planned initiation of Phase 2a study in U.S. of OncoHist™ in r/r AML
and, possibly, a second leukemia indication
 FY16 – Complete outlicensing/partnering of ErepoXen®candidate





Strategic Partners: Clinical Milestones and Newsflow

 1H15 – Final Ph 2a report on novel multiple sclerosis vaccine, MyeloXen®
in Russia. Utilizing XBIO’s liposomal patents. 50% owned by XBIO for WW
rights.
 2H15 – Initiate Ph 2 trial with PulmoXen® in Cystic Fibrosis in Russia
 2H15 – Commence MyeloXen® Ph 2b trials in Russia
 2H15 - Commence PSA-oxyntomodulin Ph 2a trials in Russia
 2H15 – Ph 2a India in-center dialysis IV administration, final report
 2H15 – Update on ErepoXen® Ph 2b Russia 30 patient clinical trial
 1H16 – Baxter IND submission for BAX826 (PSA FVIII)









UP OVER 45%



OT: XBIO
$ 0.40 0.13 (45.46%)
Day High: 0.43
Day Low: 0.25
Volume: 48,800 3:14 PM ET
Jul 29, 2015
Delayed ~20 min., by eSignal.

buywell3
29/7/2015
18:27
The dilution following a warrant conversion might not be so bad, and at least XEN is showing that it still has a pulse. Volume traded is increasing, though in money terms not a lot. Could just be a pump and dump operation following a broker rec, Who knows !
corrientes
29/7/2015
17:39
I'd almost given up on this one but finally a bit of liquidity has booted the price back up a bit, still some way to go though!Guess there's some news pending.
heyho2
29/7/2015
16:32
up big today? anyone have any news?
ih_132094
15/7/2015
07:59
Xenetic Biosciences Reports Phase 2 Data on Drug Candidate ErepoXen(R) for Anemia





Hemoglobin Levels Rose and were Maintained in Therapeutic Range

ErepoXen was Generally Well Tolerated With No Significant Treatment-related Adverse Events

Compound uses Patented PolyXen® Technology for Recombinant Erythropoietin

LEXINGTON, Mass., July 14, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that it has completed treatment of the second cohort of its Phase 2 dose-escalation study with its lead drug candidate ErepoXen® for the treatment of anemia in pre-dialysis chronic kidney disease patients. The 12 patients enrolled in this cohort received a biweekly injection of ErepoXen® until hemoglobin levels reached the therapeutic range. The patients then received injections of ErepoXen® every 4 weeks (extended dosing interval) during maintenance for a total trial time of 17 weeks.

The data show 91% of the enrolled patients had an increase in hemoglobin levels over time, and that in 75% of the enrolled patients, hemoglobin levels rose over time into the therapeutic range of 10-12 g/dL. The cohort average hemoglobin level reached the therapeutic range between weeks 4 and 6 after initiation of therapy. Hemoglobin levels were then maintained within the therapeutic range for the remainder of the 17-week study. This compares favorably with the first cohort of 12 patients, which showed an increase in the average hemoglobin levels over the course of the 17-week study but did not significantly penetrate the desired hemoglobin therapeutic range. In both cohorts, ErepoXen® was generally well tolerated and there were no treatment related significant adverse events. The study was conducted at 10 treatment sites, including eight in Australia and two in New Zealand. A third cohort has been planned to study the effects of an increased dose of ErepoXen® with the objective of ascertaining the optimal therapeutic dose level.

Professor Simon D Roger M.D., FRACP, Director of Renal Medicine, Gosford Hospital, New South Wales, Australia and principal investigator of the study, said, "The results achieved with ErepoXen® in these chronic kidney disease patients are encouraging and should lead to continued study of this compound. We have finished the process of preparing for the third cohort and determining the dose and interval for administration to be studied in this group. We are very encouraged about the potential for ErepoXen® to treat these patients and look forward to providing additional data on the third cohort in 2015."

"Our lead investigational drug candidate, ErepoXen®, continues to generate exciting data as a potential new treatment option for anemia patients, a global market that exceeds $7 billion annually" said M. Scott Maguire, Chief Executive Officer of Xenetic. "In addition, these results increase our confidence in the potential of Xenetic's PolyXen® technology to create new, next generation therapeutics from existing, approved therapeutics. In the present case, the use of Xenetic's patented technology has significantly changed the biological half-life of erythropoietin while maintaining its pharmacological activity in humans. We expect that this technology may be applicable to a large variety of therapeutic compounds, not only modifying their biological properties, but also generating new patent exclusivities".

lordgibil
14/7/2015
23:27
Some good news out regarding erepoxen trials on xenetic's home page if anyone is still out there.
lordgibil
10/7/2015
05:13
3m dollar funding for 10% potential holding in 1 yr with pharmsynthez.
lordgibil
02/6/2015
15:39
Guys as per my earlier post dont lose faith - things are progressing behind the scenes we just need to get the Russians and Indians on the same page re the capital restructure required to list on Nasdaq, once this is complete and we get uplift we can put this whole sorry episode behind us
trotterstrading
19/5/2015
07:26
and here's me thinking this was a silence contest to see how long the PI pain could be endured. Worse than my sciatica !
corrientes
19/5/2015
06:07
This is painful!
heyho2
01/5/2015
06:01
Seems we all missed this news:

LEXINGTON, Mass., April 21, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces the resignation of Chairman Mark Leuchtenberger.

CEO of Xenetic Scott Maguire said, "We want to thank Mark for his seasoned board guidance over the last year, helping a previously European company navigate the complex US regulatory environment. Unfortunately the demands of his new CEO position at Chiasma make it impossible to maintain his chairman's role for Xenetic. I want to thank Mark again for his service the past year and I wish him luck in his new venture."

The company plans to keep the chair role vacant until a suitable candidate can be found.

lordgibil
27/4/2015
12:36
The bridge loan is not an issue, that should be wrapped up imminently. The larger issue is doing the re-org and fund raise required to uplift to Nasdaq, for that we need all the major shareholders and external funds to get on the same page
trotterstrading
Chat Pages: 178  177  176  175  174  173  172  171  170  169  168  167  Older

Your Recent History

Delayed Upgrade Clock